SS
KROS icon

Sunbelt Securities’s Keros Therapeutics KROS Stock Holding History

Sunbelt Securities’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44 Sell
4
-6
-60% -$93 ﹤0.01% 2789
2025
Q4 		$204 Buy
10
+3
+43% +$53 ﹤0.01% 2430
2025
Q3 		$111 Buy
+7
New +$103 ﹤0.01% 2498

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Sunbelt Securities's KROS Position: Q1 2026 in Review

Sunbelt Securities reduced its Keros Therapeutics (KROS) stake by 60% in Q1 2026, selling an estimated $93 and leaving 4 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #2789.

Sunbelt Securities first reported a position in KROS in Q3 2025 and has held it in 3 quarters since. The position peaked at $204 in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Sunbelt Securities held 4 shares of Keros Therapeutics worth $44 as of Q1 2026.
  • Sunbelt Securities sold 6 Keros Therapeutics shares in Q1 2026, an estimated $93.
  • Keros Therapeutics made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2789 holding.
  • Sunbelt Securities first reported a position in Keros Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Sunbelt Securities's Keros Therapeutics position peaked at $204 in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.